Drugs / Pelargonium sidoides extract
Pelargonium sidoides extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07017335 | Jun → Jul 2025 | — | Pharmbio Korea Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07161180 Background | Aug → Oct 2025 overdue | — | Pharmbio Korea Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT01420445 Comparator | Sep 2011 → May 2012 | chronic bronchitis | Yuhan Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pelargonium sidoides extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01420445 ↗ |
| Known as | Pelargonium sidoides 11% ethanol extract | “R2\_PBK\_M2301 (Pelargonium sidoides 11% ethanol extract)” NCT07017335 ↗ |
| Known as | R2_PBK_M2301 | “R2_PBK_M2301 (Pelargonium sidoides extract)” NCT07017335 ↗ |
| Route | Oral | “R2\_PBK\_M2301 is an oral tablet” NCT07017335 ↗ |